IFCT at #ESMO24 with 3 studies presented : IFCT-1401 BR.31, IFCT-1904 ENCO-BRAF & IFCT-1802 SAVIMMUNE #NSCLC #Immunotherapy ESMO - Eur. Oncology ifct.fr/component/acym…

Presented at #ESMO24: Among patients with limited-stage small-cell lung cancer, overall and progression-free survival were significantly longer with durvalumab adjuvant therapy added to standard concurrent chemoradiotherapy. Full ADRIATIC trial results: nej.md/4d0eZ5m

First #NSCLC presentation #ESMO2024 BR-31 trial conducted by several groups including CCTG IFCT lung Durvalumab vs Placebo in adjuvant setting: negative trial (DFS), no impact of PDL1 status. Pre/Peri-op strategy remains the SoC. OncoAlert ESMO - Eur. Oncology

ESMO 24 LeCancer.fr lecancer.fr/congres/%25con…

💊 Phase 1/2 ALKOVE-1 study of NVL-655 in ALK+ solid tumors presented by Alexander Drilon MD 🌟 Remarkable ORR across different settings with many durable responses and 🧠 activity, and TRK-sparing tox confirming the drug design rational. #ESMO24 #LCSM

Encouraging treatment for our ROS1 patients Benjamin Besse #ESMO24

Dr. Yilong Wu Thomas Wu presents early data from PM8002 / BNT327 (PD-L1 VEGF-A bispecific antibody) plus chemotherapy in #EGFR mutant NSCLC post TKI at #ESMO24. #ESMOAmbassadors

Dr. Benjamin Besse presents data from ARROS-1 study of NVL-520 (zidesamtinib) in #ROS1 NSCLC. RP2D established at 100mg daily. Rationally designed drug with high CNS efficacy and avoiding TRK will help reduce toxicity. #ESMO24 #ESMOAmbassadors

#ESMO24 Dr. Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ presents data on zipalertinib in NSCLC with an #EGFR exon 20 mutation post amivantamab. RR post ami 50% and including post ami and other EGFRex20 agents, RR 40%. mPFS 9.7 months. Reassuring safety profile. #ESMOAmbassadors

AEGEAN; ctDNA update ; all pts with pCR had ctDNA clearance; pts without clearance unlikely to get pCR #ESMO24

One of the criticisms of LAURA at ASCO24 was we didn’t know the staging details: how many had PET staging? We now know- 55% and importantly the strong and meaningful benefit is still there in PET staged (HR=0.24), reinforcing strong osi benefit. #ESMO24 ESMO - Eur. Oncology

Sanjay Popat ESMO - Eur. Oncology Agree. The abysmal control arm was equally awful in pet staged patients. This has important implications

Can inhaled corticosteroid reduce RT induced lung damage during radical lung rt for unresectable IIIa/b?; n292; yes it can. 15% reduction in radiation pneumonitis. #ESMO24 lovely trial; practice changing #ESMO24

Agree with you Balazs Halmos

📽️We are live! Watch our reports from #ESMO24, for free and on demand: high5oncology.tv/meeting-covera… #high5oncologyTV Stephen V Liu, MD Dr Riyaz Shah Frank Griesinger Martin Reck Noemi Reguart Lizza Hendriks Nicolas Girard denis Moro-Sibilot Hossein Borghaei, DO Sacha Rothschild joaquim bellmunt Anders Bjartell

Joshua Reuss Sandra Ortiz-Cuaran d.planchard IFCT-sponsored : French Intergroup IFCT lung

I think we are fooling ourselves if we think that anatomic staging with CT/PET/brain MR in unresectable stage III does much to reduce the proportion of patients with underlying micrometastatic disease, especially in EGFR-mutated disease! So many of these patients even with

FDA approves first-line pembrolizumab plus platinum + pemetrexed (up to 6 cycles) for advanced malignant pleural #mesothelioma. Based on KEYNOTE-483 (IND 227) that showed adding pembrolizumab improved OS (HR 0.79). fda.gov/drugs/resource…

Why hasn't there been more discussion about this study? I'm surprised because it clearly shows another carcinogenic pathway (potentially targetable?) and the need to discuss screening strategies! At #ESMO24 Dr Alexis Cortot presented data from a French study that showed a

#ESMO24: Lung cancer in focus Latest findings and practice changing data – on #high5oncologyTV, free & on demand! high5oncology.tv/meeting-covera… Stephen V Liu, MD Dr Riyaz Shah Frank Griesinger Martin Reck Noemi Reguart Lizza Hendriks Nicolas Girard denis Moro-Sibilot Hossein Borghaei, DO Sacha Rothschild